Fused ring compound, and preparation method therefor and use thereof

By designing novel camptothecin compounds and their conjugates, the problems of insufficient safety and efficacy of existing camptothecin drugs in antitumor treatment have been solved, achieving antitumor effects with low efflux rate and good metabolic stability.

WO2024227440A1PCT designated stage expired Publication Date: 2024-11-07SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090825
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-13
Filing Date
2024-04-30
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Existing camptothecin-based drugs have hematologic toxicity and gastrointestinal side effects in antitumor treatment, necessitating the development of novel compounds with improved safety and efficacy.

Method used

A class of novel camptothecin compounds and their conjugates were designed, exhibiting good antitumor activity, excellent permeability, and low efflux rate. They were prepared via synthetic routes including Friedel-Crafts acylation, ring-closing reaction, Delépine reaction, and condensation reaction.

Benefits of technology

These compounds exhibit low efflux rates and good metabolic stability, possess high antitumor activity, can overcome drug resistance, and are suitable for treating a variety of cancer diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024090825_07112024_PF_FP_ABST
    Figure CN2024090825_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a fused ring compound, and a preparation method therefor and the use thereof. Specifically, the present application relates to a compound as represented by the following formula or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor and the use thereof. The compound can be used as a drug for treating diseases related to abnormal cell proliferation.
Need to check novelty before this filing date? Find Prior Art

Description

Condensed ring compound and its preparation method and application

[0001] This application is based on PCT application number PCT / CN2023 / 092019, filed on May 4, 2023, CN application number 202310538792.7, filed on May 12, 2023, CN application number 202311116153.8, filed on August 31, 2023, CN application number 202311258765.0, filed on September 27, 2023, and CN application number 202311327100.0, filed on October 13, 2023, and claims priority from them. The disclosed contents of these applications are hereby introduced as a whole into this application. Technical Field

[0002] The present application relates to a class of fused ring compounds, as well as their preparation methods and applications in the medical field. Background Art

[0003] Camptothecin (CPT) is a pentacyclic compound isolated from Camptotheca acuminata (see the structural formula below). Due to its excellent anticancer activity, it was introduced into clinical practice in the early 1970s. However, clinical trials were subsequently discontinued due to severe side effects such as vomiting, diarrhea, and hair loss.

[0004] Camptothecin and its derivatives have strong anti-tumor activity in animal models of ovarian, lung, colorectal, and breast cancer (Nature Review Cancer. 2006, 6, 789). Research data show that camptothecin can form a ternary complex with cellular DNA topoisomerase I, thereby inhibiting DNA unwinding, leading to DNA replication blockage and cell death (Cancer Res. 1989, 49, 6365).

[0005] Currently, several camptothecins have been approved for the treatment of tumors (Med. Res. Rev. 2015, 35, 753), for example, belotecan for the treatment of ovarian cancer and small cell lung cancer, topotecan for ovarian cancer, and irinotecan for the treatment of colorectal cancer.

[0006] Camptothecin drugs or derivatives often have hematotoxicity and gastrointestinal side effects. The hematotoxicity is caused by bone marrow suppression, which is manifested as thrombocytopenia, anemia, neutropenia, leukopenia, etc. Gastrointestinal adverse reactions include diarrhea, nausea, vomiting, etc. Clinical studies have found that it is possible to improve the safety and efficacy of camptothecin compounds by adjusting the activity of camptothecin compounds, improving the pharmacokinetic properties of camptothecin compounds, reducing the dosage, or forming antibody-drug conjugates with antibodies. Therefore, the research and development of camptothecin compounds and their conjugates with novel structures that can improve efficacy and improve safety issues still has a high clinical demand and application value.

[0007] Summary of the Invention

[0008] The present application provides novel camptothecin compounds and their conjugates. The camptothecin compounds have good anti-tumor activity, excellent permeability, low efflux rate, and good metabolic stability, and are expected to be used in the treatment of tumor diseases; their conjugates have broad application prospects in antibody-drug conjugates.

[0009] In a first aspect, the present application provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, wherein the compound has the structure shown below:

[0010] in,

[0011] R1 is fluorine or chlorine,

[0012] When R1 is fluorine, R2 is methyl or chlorine;

[0013] When R1 is chlorine, R2 is methyl;

[0014] Alternatively, R1 and R2 together with adjacent carbon atoms (ring-forming carbon atoms connecting R1 and R2, respectively) form a five-membered oxygen-containing heterocyclic ring

[0015] R3 is hydrogen or methyl;

[0016] A is selected from:

[0017] When R1 is fluorine and R2 is methyl, A is not a hydroxyacetamide group.

[0018] In some embodiments, when R1 and R2 form a five-membered oxygen-containing heterocyclic ring with adjacent carbon atoms, When A is not a hydroxyacetamide group.

[0019] In some embodiments, when R1 is fluoro and R2 is methyl, A is not

[0020] In some embodiments, the compound of formula (I):

[0021] A is selected from:

[0022] In some embodiments, the compound of formula (I):

[0023] A is selected from:

[0024] In some embodiments,

[0025] R1 is fluorine,

[0026] R2 is methyl or chlorine;

[0027] Alternatively, R1 and R2 form a five-membered oxygen-containing heterocyclic ring with adjacent carbon atoms. and

[0028] A is selected from:

[0029] In some embodiments, the compound of formula (I):

[0030] R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring carbon atoms connecting R1 and R2 respectively form

[0031] R3 is a methyl group;

[0032] A is selected from:

[0033] In some embodiments, the compound of formula (I):

[0034] R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl;

[0035] R3 is a methyl group;

[0036] A is selected from:

[0037] In some embodiments, the compound of formula (I):

[0038] R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring carbon atoms connecting R1 and R2 respectively form

[0039] R3 is a methyl group;

[0040] A is selected from:

[0041] In some embodiments, the compound of formula (I):

[0042] R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl;

[0043] R3 is a methyl group;

[0044] A is selected from:

[0045] In some embodiments, the compound of formula (I):

[0046] R1 is fluorine, R2 is selected from methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring carbon atoms connecting R1 and R2 respectively form

[0047] R3 is hydrogen;

[0048] A is selected from:

[0049] In some embodiments, the compound of formula (I):

[0050] R1 is fluorine, R2 is selected from methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring carbon atoms connecting R1 and R2 respectively form

[0051] R3 is hydrogen;

[0052] A is selected from:

[0053] In some embodiments, the compound of formula (I):

[0054] R1 is fluorine, R2 is methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring carbon atoms to which R1 and R2 are respectively connected form

[0055] R3 is hydrogen;

[0056] A is selected from:

[0057] In a second aspect, the present application provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite, and prodrug thereof, wherein the compound has the structure shown below:

[0058] in,

[0059] R1 is halogen,

[0060] R2 is substituted or unsubstituted C 1-6 alkyl;

[0061] Alternatively, R1 and R2 together with adjacent carbon atoms (ring-forming carbon atoms connecting R1 and R2, respectively) form a substituted or unsubstituted heterocyclic ring;

[0062] R3 is selected from hydrogen or substituted or unsubstituted C 1-6 alkyl; and

[0063] A is selected from the following substituted or unsubstituted groups:

[0064] In some embodiments, in the compound of formula (II): R1 is fluoro or chloro.

[0065] In some embodiments, in the compound of formula (II): when R1 is fluorine, R2 is selected from substituted or unsubstituted C 1-6 Alkyl or chlorine; when R1 is chlorine, R2 is selected from substituted or unsubstituted C 1-6 alkyl.

[0066] In some embodiments, the compound of formula (II):

[0067] When R1 is fluorine, R2 is methyl or chlorine; when R1 is chlorine, R2 is methyl.

[0068] In some embodiments, in the compound of formula (II), R1 and R2 form a substituted or unsubstituted five- to six-membered oxygen-containing heterocyclic ring with adjacent carbon atoms.

[0069] In some embodiments, in the compound of formula (II), R1 and R2 form a substituted or unsubstituted five-membered oxygen-containing heterocyclic ring with adjacent carbon atoms.

[0070] In some embodiments, in the compound of formula (II): R1 and R2 form a substituted or unsubstituted five-membered oxygen-containing heterocyclic ring with adjacent carbon atoms.

[0071] In some embodiments, the compound of formula (II):

[0072] When R1 is fluorine, R2 is methyl or chlorine;

[0073] When R1 is chlorine, R2 is methyl; or

[0074] R1 and R2 form a five-membered oxygen-containing heterocyclic ring with adjacent carbon atoms

[0075] R3 is hydrogen or methyl; and

[0076] A is selected from:

[0077] In some embodiments, the compound of formula (II):

[0078] R1 is fluorine;

[0079] R2 is methyl or chlorine;

[0080] R3 is hydrogen;

[0081] A is selected from:

[0082] Another aspect of the present application provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, wherein the compound has the structure shown below:

[0083] Another aspect of the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, wherein the compound has the structure shown below:

[0084] definition

[0085] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.

[0086] The terms "comprises," "comprising," "having," "containing," or "involving," and variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.

[0087] As used herein, the "*" marked in a compound structural formula indicates that the marked carbon atom is a chiral carbon atom, and the present invention includes a pair of enantiomers formed by this chiral carbon atom. If a compound contains two different chiral carbon atoms, the present invention includes the four optical isomers formed by these chiral carbon atoms.

[0088] As used herein, Indicates the site where the structural fragment is connected to the rest of the molecule.

[0089] The term "alkyl" is defined as a straight or branched chain saturated aliphatic hydrocarbon group. In some embodiments, the alkyl group has 1 to 12, such as 1 to 6, carbon atoms. For example, as used herein, the term "C 1-6 "Alkyl" refers to a linear or branched group of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl), which is optionally substituted by 1 or more (such as 1, 2 or 3) suitable substituents.

[0090] The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing at least one carbon-carbon double bond, including, for example, "C 2-6 Alkenyl", "C 2-4 Examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexadienyl, and the like.

[0091] The term "alkynyl" refers to a straight or branched chain hydrocarbon group containing at least one carbon-carbon triple bond. 2-6 Alkynyl", "C 4-6 Examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1,3-butadiynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,4-hexadiynyl, and the like.

[0092] The term "cycloalkyl" refers to a saturated cyclic hydrocarbon group, including but not limited to monocyclic alkyl and bicyclic alkyl (such as spirocyclic alkyl, bicyclic alkyl and bridged cycloalkyl). 3-6 "Cycloalkyl" refers to a cycloalkyl group having 3 to 6 ring carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc., which may be optionally substituted with 1 or more (such as 1, 2 or 3) suitable substituents, for example methyl substituted cyclopropyl.

[0093] The term "carbocycle" or "carbocyclyl" refers to a saturated or partially unsaturated non-aromatic monocyclic or polycyclic structure, a hydrocarbon group connected through a ring carbon. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0094] The term "carbocycle" refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (for example, a monocyclic ring such as a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, a cyclononane ring, or a bicyclic ring, including a spirocyclic, fused or bridged system (such as a bicyclo[1.1.1]pentane ring, a bicyclo[2.2.1]heptane ring, a bicyclo[3.2.1]octane ring or a bicyclo[5.2.0]nonane ring, a decalin ring, etc.), which may be optionally substituted with one or more (such as one, two or three) suitable substituents. The term "3-6 membered carbocycle" refers to a carbocycle containing 3, 4, 5 or 6 ring-forming carbon atoms.

[0095] The term "heterocyclyl" or "heterocycle" refers to a saturated or partially saturated, monocyclic or polycyclic (such as a bicyclic) non-aromatic cyclic structure, the ring atoms of which are composed of carbon atoms and at least one (e.g., 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, and sulfur. If the valence bond requirements are met, the heterocyclyl can be connected to the rest of the molecule via any one of the ring atoms. The heterocyclyl in the present invention is preferably a 3-6 membered heterocyclyl. The term "3-6 membered heterocyclyl" used in the present invention refers to a heterocyclyl having 3 to 6 ring atoms, including 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, and 6-membered heterocyclyl, including nitrogen-containing heterocyclyl, oxygen-containing heterocyclyl, such as 4-6 membered heterocyclyl, such as 4-6 membered nitrogen-containing heterocyclyl, 4-6 membered oxygen-containing heterocyclyl, 5-6 membered oxygen-containing heterocyclyl, and 5-membered oxygen-containing heterocyclyl. Common heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, pyrrolidinonyl, imidazolidinyl, pyrazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, and morpholinyl. The heterocyclic groups of the present invention may be optionally substituted with one or more substituents described herein. The heterocyclic groups of the present invention may be optionally fused to one or more aromatic or non-aromatic rings.

[0096] The term "oxygen-containing heterocycle" refers to a heterocycle as described above in which one or more (e.g., 1, 2, or 3) ring atoms are oxygen atoms, such as a 5-6 membered oxygen-containing heterocycle, a 5-membered oxygen-containing heterocycle, and specific examples include but are not limited to an oxirane ring, a tetrahydrofuran ring, a furan ring, a tetrahydropyran ring, a pyran ring, a 1,3-dioxolane ring, and the like.

[0097] The "nitrogen-containing heterocycle" described in the present invention refers to a heterocycle as described above in which one or more (eg, 1, 2 or 3) ring atoms are nitrogen atoms.

[0098] The term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1, 2 or 3) the same or different halogen atoms, wherein alkyl is defined as above. For example, the term "C 1-6 "Haloalkyl" refers to a haloalkyl group having 1 to 6 carbon atoms. Common haloalkyl groups include (but are not limited to) -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, -CH2CH2CF3, -CH2Cl, etc. The haloalkyl group in the present invention is optionally substituted with one or more substituents described herein.

[0099] The term "alkoxy" refers to a group having the structure "alkyl-O-", wherein alkyl is as defined above. 1-6 Alkoxy, C 1-4 Alkoxy, C 1-3 Alkoxy or C 1-2 Alkoxy, etc. Common alkoxy groups include (but are not limited to) methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, etc. The alkoxy group in the present invention is optionally substituted with one or more substituents described herein.

[0100] The term "alkoxyalkyl" refers to an alkyl group substituted by one or more (e.g., 1, 2, 3, or 4) alkoxy groups, wherein alkoxy and alkyl are as defined above. For example, the term "C 1-6 "Alkoxyalkyl" refers to an alkyl group having 1-6 carbon atoms, substituted by one or more (e.g., 1, 2, 3, or 4) alkoxy groups. Common alkoxyalkyl groups include (but are not limited to) CH3O-CH2-, C2H5-O-CH2-, C2H5-O-CH2CH2-, etc.

[0101] The term "halo" or "halogen" group is defined to include F, Cl, Br, or I.

[0102] The term "hydroxyacetamido" refers to

[0103] The term "nitrogen oxide" refers to an oxide (eg, mono- or di-oxide) of at least one nitrogen atom in the structure of the present invention. Nitrogen mono-oxides may exist as a single positional isomer or a mixture of positional isomers.

[0104] If a substituent is described as being "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more substituents from the list of substituents, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and / or collectively, with independently selected optional substituents. If a nitrogen of a substituent is described as being optionally substituted with one or more substituents from the list of substituents, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected optional substituent.

[0105] If a functional group or structural moiety is described as "substituted or unsubstituted," the functional group or structural moiety may be (1) unsubstituted or (2) substituted.

[0106] The term "substituted" refers to the replacement of one or more (e.g., 1, 2, 3, 4, or 5) hydrogen atoms on a designated compound or structural fragment by a substituent, provided that the normal valence of the designated atom in the present case is not exceeded and the substitution forms a stable compound. Combinations of substituents and / or variables are permitted only if such combinations form stable compounds. For example, the substituents are each independently composed of one or more of the following structures: -O-, -S-, -NR'-, halogen, -CN, -OH, -NH2, -NO2, -CN, =O, C 1-6 (Ethylene) alkyl, C 1-6 Halogenated (ene) alkyl, C 1-6 Alkoxy, C 2-6 (Ethylene) alkenyl, C 2-6 (Ene) alkynyl, C 3-8 (Ethyl) cycloalkyl, 3-8 membered (ethyl) heterocyclic group, C 6-10 (E)aryl and 5-10 membered (E)heteroaryl, etc. If a substituent is described as being "independently selected" from a group of functional groups, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.

[0107] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, where reasonable.

[0108] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.

[0109] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In a compound with one or more (e.g., one, two, three, or four) asymmetric centers, it can produce a racemic mixture, a single enantiomer, a diastereomeric mixture, and a separate diastereomer. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is understood that the scope of this application encompasses all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%).

[0110] In this article, solid lines can be used Solid wedge or virtual wedge The carbon-carbon bonds of the compounds of the present invention are depicted. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomers exist. When present in a racemic mixture, solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to exist as stereoisomers, including cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).

[0111] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.

[0112] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.

[0113] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.

[0114] Suitable acid addition salts are formed from acids that form pharmaceutically acceptable salts and include aspartate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, and the like.

[0115] Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts, including aluminum salts, arginine salts, choline salts, diethylamine salts and the like.

[0116] For a review of suitable salts see Stahl and Wermuth, “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds of the invention are known to those skilled in the art.

[0117] The term "ester" refers to esters derived from the compounds of the general formula herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.

[0118] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.

[0119] Also included within the scope of the present invention are metabolites of the compounds of the present invention, i.e., substances formed in vivo upon administration of the compounds of the present invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic hydrolysis, and the like of the administered compound. Thus, the present invention includes metabolites of the compounds of the present invention, including compounds produced by contacting a compound of the present invention with a mammal for a period of time sufficient to produce a metabolic product thereof.

[0120] The present invention further includes within its scope prodrugs of the compounds of the present invention. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compound in vivo. Therefore, in these cases, the term "administering" as used in the methods of treatment of the present invention should include treating various diseases or conditions with one or more prodrug forms of the claimed compounds, but the prodrug forms are converted into the aforementioned compounds in vivo after administration to the individual. For example, "Design of Prodrug", ed. H. Bundgaard, Elsevier, 1985, describes conventional methods for selecting and preparing suitable prodrug derivatives.

[0121] The present invention further includes within its scope isotopically labeled compounds of the invention which are identical to the compounds of the invention except that one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature.

[0122] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P.GM Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.

[0123] Pharmaceutical composition

[0124] In a third aspect, the present application provides a pharmaceutical composition comprising the compound described in the first or second aspect of the present application or its pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug, and one or more pharmaceutically acceptable carriers.

[0125] The term "pharmaceutical composition" refers to a composition that can be used as a medicament, which comprises an active pharmaceutical ingredient (API) (or therapeutic agent) and, optionally, one or more pharmaceutically acceptable carriers. The term "pharmaceutically acceptable carrier" refers to an excipient that is administered with a therapeutic agent and that is suitable, within the scope of sound medical judgment, for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic reaction, or other problems or complications commensurate with a reasonable benefit / risk ratio.

[0126] The pharmaceutical compositions can act systemically and / or locally, which can be achieved by suitable dosage forms, including but not limited to tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, and syrups.

[0127] The pharmaceutical composition may contain 0.01 mg to 1000 mg of at least one compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof.

[0128] The present invention also provides a method for preparing the above-mentioned pharmaceutical composition or its corresponding formulation, which comprises combining at least one compound of the present invention or its pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug with one or more pharmaceutically acceptable carriers.

[0129] Medicine box products

[0130] In a fourth aspect, the present application provides a medicine kit product comprising:

[0131] a) at least one compound of the first or second aspect or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled compound, metabolite or prodrug thereof as a first therapeutic agent, or the pharmaceutical composition of the third aspect as a first pharmaceutical composition;

[0132] b) optionally at least one additional therapeutic agent as a second therapeutic agent, or a pharmaceutical composition comprising an additional therapeutic agent as a second pharmaceutical composition; and

[0133] c) optional packaging and / or instructions.

[0134] The above-mentioned kit product may contain 0.01 mg to 1000 mg of at least one compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof.

[0135] The present invention also provides a method for preparing the above-mentioned drug kit, which comprises combining at least one compound of the present invention or its pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug or the above-mentioned pharmaceutical composition with at least one other therapeutic agent or pharmaceutical composition containing other therapeutic agents, packaging and / or instructions.

[0136] Medical uses

[0137] The compound of the present invention can exhibit a strong effect of inhibiting abnormal cell proliferation.

[0138] Therefore, the present application provides a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, the above-mentioned pharmaceutical composition or the above-mentioned drug kit product, which is used to treat diseases related to abnormal cell proliferation.

[0139] In addition, the present application also provides the use of the compounds of the present invention or their pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope-labeled substances, metabolites and prodrugs, the above-mentioned pharmaceutical compositions or the above-mentioned drug kit products in the preparation of drugs for treating diseases related to abnormal cell proliferation.

[0140] In some embodiments, the disease associated with abnormal cell proliferation includes, but is not limited to, a tumor, such as an advanced solid tumor.

[0141] The present application also provides the use of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof or a pharmaceutical composition of the present invention in the preparation of a preparation for inhibiting the proliferation of tumor cells. In certain embodiments, the preparation is used for in vivo or in vitro administration. For example, the preparation can be administered to a subject to inhibit the proliferation of tumor cells in the subject; alternatively, the preparation can be administered to in vitro cells (e.g., cell lines or cells from a subject) to inhibit the proliferation of tumor cells in vitro.

[0142] The tumors described in the present invention include (but are not limited to): brain tumor, lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female reproductive tract cancer, carcinoma in situ, lymphoma, neurofibroma, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.

[0143] Treatment

[0144] In another aspect, the present application provides a method for treating diseases associated with abnormal cell proliferation, comprising the following steps: administering a therapeutically effective amount of a compound of the present invention or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope labels, metabolites and prodrugs or the above-mentioned pharmaceutical compositions to an individual in need thereof.

[0145] The term "effective amount" refers to a dose that can induce a biological or medical response in cells, tissues, organs or organisms (eg, individuals) and is sufficient to achieve the desired preventive and / or therapeutic effect.

[0146] The dosage regimen can be adjusted to provide the optimal desired response. For example, the drug may be administered in a single dose, divided doses may be administered over time, or the dosage may be proportionally reduced or increased based on the actual situation. It will be understood that for any particular individual, the specific dosage regimen should be adjusted according to the needs and the professional judgment of the person administering the composition or supervising the administration of the composition.

[0147] The dosage of the compound of the present invention will depend on the individual situation, the severity of the disease or illness, the rate of administration, the disposal of the compound and the judgment of the prescribing physician. Generally speaking, the effective amount is about 0.001-10000mg / kg subject body weight / day. In appropriate cases, the effective amount is about 0.01-1000mg / kg subject body weight / day. About 0.01-1000mg / kg subject body weight, usually about 0.1-500mg / kg subject body weight, can be administered every day, every two days or every three days. An exemplary dosage regimen is once a day or more, or once a week or more, or once a month or more. During multiple administration, the intervals between single doses can generally be daily, weekly, monthly or annual. Alternatively, it can be administered in the form of a sustained-release formulation, in which case a lower frequency of administration is required. Dosage and frequency can vary according to the half-life of the drug in the subject, or can vary according to whether it is a preventive application or a therapeutic application. In preventive applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time; in therapeutic applications, a relatively high dosage is sometimes required at shorter intervals until the progression of the disease is slowed or stopped, preferably until the individual exhibits partial or complete improvement in disease symptoms, after which preventive applications can be employed.

[0148] The term "treat" refers to the alleviation or elimination of a targeted disease or condition. If a subject receives a therapeutic amount of a compound of the present invention, or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention, and at least one indicator or symptom of the subject exhibits observable and / or detectable relief and / or improvement, the subject has been successfully "treated." It will be understood that treatment encompasses not only complete treatment but also less than complete treatment while achieving some biologically or medically relevant outcome.

[0149] The term "administrate / administrating / administration" (or "dosage") refers to the process of applying a pharmaceutically active ingredient (such as a compound of the present invention) or a pharmaceutical composition comprising a pharmaceutically active ingredient (such as a pharmaceutical composition of the present invention) to an individual or its cells, tissues, organs, biological fluids, and other parts, so as to bring the pharmaceutically active ingredient or pharmaceutical composition into contact with the individual or its cells, tissues, organs, biological fluids, and other parts. Common administration routes include (but are not limited to) oral administration, subcutaneous administration, intramuscular administration, subperitoneal administration, ocular administration, nasal administration, sublingual administration, rectal administration, vaginal administration, and the like.

[0150] The term "in need of" refers to a physician's or other health care provider's judgment that an individual needs or will benefit from a preventive and / or therapeutic procedure, which judgment is based on various factors within the physician's or other health care provider's area of ​​expertise.

[0151] The term "individual" (or subject) refers to a human or non-human animal. The individual of the present invention includes individuals (patients) suffering from a disease and / or condition and normal individuals. The non-human animals of the present invention include all vertebrates, such as non-mammals, such as birds, amphibians, reptiles, etc., and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0152] Preparation method

[0153] The fifth aspect of the present application provides a method for synthesizing the compound of the present invention.

[0154] Method A: The compounds of formula (I) and formula (II) of the present invention can be synthesized by the following synthetic routes:

[0155] Wherein, R1 and R2 have the same meanings as above, R4 is hydroxyl, and R5 are each independently selected from hydrogen, C 1-6 Alkyl, cyclopropyl, n is selected from 1, 2 or 3;

[0156] R3 is selected from hydrogen and methyl, and A is selected from:

[0157] Step 1

[0158] Compound (I)-SM1 and compound (I)-SM2 undergo Friedel-Crafts acylation to obtain compounds of formula (I)-IM1 and formula (II)-IM1;

[0159] In some embodiments, this step is performed at a suitable temperature, such as 5°C, 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, preferably 25°C.

[0160] Step 2

[0161] Compounds of formula (I)-IM1, formula (II)-IM1 and compound (I)-SM3 undergo a ring-closing reaction under acidic conditions to obtain compounds of formula (I)-IM2 and formula (II)-IM2;

[0162] In some embodiments, this step is carried out at a suitable temperature, which is 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 120°C, preferably 120°C;

[0163] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from toluene, xylene, o-cresol, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, preferably toluene and o-cresol;

[0164] In some embodiments, this step is performed under acidic conditions;

[0165] Reagents providing acidic conditions include p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, formic acid, sulfuric acid, and methanesulfonic acid, preferably p-toluenesulfonic acid.

[0166] Step 3:

[0167] Compounds of formula (I)-IM2 and formula (II)-IM2 undergo Delépine reaction to obtain compounds of formula (I)-IM3 and formula (II)-IM3.

[0168] In some embodiments, this step is performed at a suitable temperature, such as 5°C, 20°C, 25°C, 40°C, 50°C, 60°C, 85°C, 100°C, preferably 85°C.

[0169] Step 4:

[0170] Compound (I)-IM3, compound (II)-IM3 and compound (I)-SM4 undergo condensation reaction to obtain compounds of formula (I) and formula (II).

[0171] In some embodiments, this step is carried out at a suitable temperature, which is 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, preferably 25°C;

[0172] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from halogenated hydrocarbons (such as dichloromethane (DCM), chloroform (TCM), 1,2-dichloroethane (1,2-DCE), etc.), nitriles (such as acetonitrile (AN), etc.), N-methylpyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), tetrahydrofuran (THF), 1,4-dioxane (Dioxane), dimethyl sulfoxide (DMSO) and any combination thereof, preferably DMF.

[0173] In some embodiments, this step is carried out in the presence of a suitable base, the base including an organic base or an inorganic base, the organic base can be selected from N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), potassium tert-butoxide (t-BuOK) and pyridine (Py), the inorganic base can be selected from potassium phosphate (K3PO4), sodium hydride (NaH), potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium bicarbonate (NaHCO3), cesium carbonate (Cs2CO3) and NaOH, preferably DIPEA;

[0174] In some embodiments, this step is carried out in the presence of a suitable condensing agent, which includes HATU, HBTU, EDCI, DCC, DMTMM and HOBT, preferably DMTMM and HATU;

[0175] Method B: The compounds of formula (I) and formula (II) of the present invention can be synthesized by the following synthetic route:

[0176] Wherein, R1 and R2 have the same meanings as above, R4 is hydroxyl, and R5 are each independently selected from hydrogen, C 1-6 Alkyl, cyclopropyl, n is selected from 1, 2 or 3;

[0177] R3 is hydrogen and methyl, and A is selected from:

[0178] Step 1

[0179] Compound (I)-IM3, compound (II)-IM3 and compound (I)-SM5 undergo condensation reaction to obtain compounds of formula (I) and formula (II).

[0180] In some embodiments, this step is carried out at a suitable temperature, which is 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, preferably 25°C;

[0181] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from halogenated hydrocarbons (such as dichloromethane (DCM), chloroform (TCM), 1,2-dichloroethane (1,2-DCE), etc.), nitriles (such as acetonitrile (AN), etc.), N-methylpyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), tetrahydrofuran (THF), 1,4-dioxane (Dioxane), dimethyl sulfoxide (DMSO) and any combination thereof, preferably DMF.

[0182] In some embodiments, this step is carried out in the presence of a suitable base, the base including an organic base or an inorganic base, the organic base can be selected from N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), potassium tert-butoxide (t-BuOK) and pyridine (Py), the inorganic base can be selected from potassium phosphate (K3PO4), sodium hydride (NaH), potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium bicarbonate (NaHCO3), cesium carbonate (Cs2CO3) and NaOH, preferably DIPEA;

[0183] In some embodiments, this step is performed in the presence of a suitable acylating agent, including triphosgene and EDCI.

[0184] intermediates

[0185] The present application provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, wherein the compound has the structure shown below:

[0186] Wherein, R1, R2 and R3 have the same meanings as described above.

[0187] The present application provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, wherein the compound has the structure shown below:

[0188] Advantageous Effects of the Invention

[0189] This application provides camptothecin compounds represented by formula (I)-formula (II), as well as pharmaceutical compositions, preparation methods, and uses thereof. These compounds have good anti-tumor activity and the potential to overcome drug resistance, and can be used to treat abnormal cell proliferation disorders, including but not limited to advanced solid tumors. DETAILED DESCRIPTION

[0190] The present application is further described below by describing specific embodiments, but this is not intended to limit the present application. Those skilled in the art can make various modifications or improvements based on the teachings of the present application without departing from the basic idea and scope of the present application.

[0191] The abbreviations used in this invention have the following meanings:

[0192] The structures of the compounds described in the following examples were determined by nuclear magnetic resonance ( 1 H NMR) or mass spectrometry (MS).

[0193] Nuclear magnetic resonance (NMR) 1 H NMR was measured using a Bruker 400 MHz nuclear magnetic resonance instrument; hexadeuterated dimethyl sulfoxide (DMSO-d6); and tetramethylsilane (TMS) as the internal standard.

[0194] The abbreviations used in the nuclear magnetic resonance (NMR) spectra in the examples are shown below.

[0195] s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, br: broad, J: coupling constant, Hz: hertz, DMSO-d6: deuterated dimethyl sulfoxide. δ values ​​are expressed in ppm.

[0196] The mass spectrometry (MS) was performed using an Agilent (ESI) mass spectrometer, model Agilent 6120B.

[0197] Example 1: (S)-N-((9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (Compound 2-1) and (S)-N-((9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (Compound 2'-1)

[0198] Step 1: Preparation of 1-(2-amino-5-chloro-4-fluorophenyl)-2-chloroethane-1-one (Compound 2-1-2) and 1-(6-amino-3-chloro-2-fluorophenyl)-2-chloroethane-1-one (Compound 2'-1-2)

[0199] Under nitrogen protection, boron trichloride (1 mol / L dichloromethane solution, 35.7 mL) was added to the reaction flask, ice water was cooled to 10-20 ° C, 4-chloro-3-fluoro-aniline (4.00 g, 27.48 mmol) in dichloroethane (60 ml) was added dropwise, and stirred at room temperature for 0.5 hours. 2-Chloroacetonitrile (4.14 g, 54.96 mmol) and aluminum chloride (4.76 g, 17.86 mmol) were added in sequence, and the temperature was raised to reflux reaction (56 ° C) overnight (16 hours). The reaction mixture was slowly poured into hydrochloric acid (2 mol / L, 60 ml), heated to 40-50°C and refluxed for 1 h. The mixture was cooled to room temperature and the product was extracted with dichloromethane (90 ml). The organic phase was washed sequentially with 2N hydrochloric acid (20 ml x 2) and brine (20 ml). The mixture was concentrated until a large amount of solid precipitated. Petroleum ether (40 ml) was added and stirred for 0.5 h. The mixture was filtered and the filter cake was dried to obtain 2.20 g of the title compound (compound 2-1-2:compound 2'-1-2 = 2.4:1).

[0200] Its structural characterization data are as follows:

[0201] ESI-MS (m / z): 222.0 [M+H] + .

[0202] Step 2: Preparation of (S)-9-chloro-11-(chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (Compound 2-1-3) and (S)-9-chloro-11-(chloromethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (Compound 2'-1-3)

[0203] A mixture of 1-(2-amino-5-chloro-4-fluorophenyl)-2-chloroethane-1-one (compound 2-1-2) and 1-(6-amino-3-chloro-2-fluorophenyl)-2-chloroethane-1-one (compound 2'-1-2) (1.60 g, 7.21 mmol) was added to toluene (30 mL), and then (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (1.99 g, 7.57 mmol) and p-toluenesulfonic acid monohydrate (685.3 mg, 3.60 mmol) were added in sequence. The temperature was raised to 110 ° C and refluxed for 8 hours. The temperature was lowered to 40-50 ° C, methanol (30 ml) was added, and the mixture was stirred and cooled to room temperature. It was filtered and the filter cake was dried to obtain the title compound (3.02 g).

[0204] Its structural characterization data are as follows:

[0205] ESI-MS (m / z): 449.0 [M+H] + .

[0206] Step 3: Preparation of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-4) and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-4)

[0207] A mixture of (S)-9-chloro-11-(chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-3) and (S)-9-chloro-11-(chloromethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-3) (3.20 g, 7.12 mmol) was suspended in ethanol (155 mL) and dimethyl sulfoxide (15 ml), and methenamine (3.05 g, 21.79 mmol) was added. ), heated to 80-85°C and reacted for 6 hours, cooled to 40-50°C, concentrated hydrochloric acid (8 ml) was added dropwise, kept at 40-50°C and stirred for 0.5 hour, about 2 / 3 of the ethanol was concentrated, and about 80 ml remained. Methyl tert-butyl ether (60 ml) was added and stirred for 2 hours, and a solid was precipitated. The solid was filtered and dried to obtain 3.85 g of solid. The crude product was added to methanol (200 ml), heated to 60-65°C and refluxed for 0.5 hour, cooled to room temperature, a small amount of insoluble solid was filtered off, filtered, and the filtrate was collected. About 2 / 3 of the methanol was concentrated, and ethyl acetate (60 ml) was added and stirred at 25°C for 1 hour. The product precipitated, filtered, and the filter cake was dried to obtain the hydrochloride salt of the title compound (2.55 g) (Compound 2-1-4: Compound 2'-1-4 = 7.4:1).

[0208] Its structural characterization data are as follows:

[0209] ESI-MS (m / z): 430.0 [M+H] + .

[0210] Step 4: Preparation of (S)-N-((9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (Compound 2-1) and (S)-N-((9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (Compound 2'-1)

[0211] A mixture of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-4) and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-4) (500 mg, 750.61 μmol, hydrochloride) was added. ) was dissolved in DMF (6 mL), DIPEA (388.0 mg, 3.00 mmol) was added and stirred for 5 minutes, followed by the addition of glycolic acid (142.7 mg, 1.88 mmol) and HATU (570.8 mg, 1.50 mmol), and the mixture was reacted at 25°C for 1 hour. Water (20 ml) was added to the system, and the product was extracted with dichloromethane (50 ml). The product was washed with 0.5N hydrochloric acid (10 ml) and brine (10 ml) in turn, and concentrated to give a crude product, which was purified by preparative HPLC and freeze-dried to give the title compounds 2-1 (20.0 mg) and 2'-1 (3.0 mg).

[0212] The structural characterization data of compound 2-1 are as follows:

[0213] MS m / z(ESI):488.1[M+H] +

[0214] 1 H NMR (400MHz, DMSO-d6) δ8.87(d,J=4.1Hz,1H),8.85(s,1H),8.19(d,J=10.3Hz,1H),7.34(s,1H),6.55(s,1H),5 .55(s,2H),5.45(s,2H),4.82(d,J=6.0Hz,2H),3.82(s,2H),1.87(dd,J=9.7,7.5Hz,2H),0.87(t,J=7.3Hz,3H).

[0215] The structural characterization data of compound 2'-1 are as follows:

[0216] MS m / z(ESI):488.1[M+H] +

[0217] 1 H NMR(400MHz,DMSO-d6)δ8.31(t,J=6.0Hz,1H),8.12-8.01(m,2H),7.35(s,1H),6.57(br,1H),5.54 (s,2H),5.45(s,2H),4.92(d,J=6.8Hz,2H),3.83(s,2H),1.90-1.83(m,2H),0.87(t,J=7.2Hz,3H).

[0218] The chromatographic conditions are as follows:

[0219] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0220] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0221] Example 2: Preparation of (S)-N-(((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-cyclopropyl-2-hydroxyacetamide (Compound 2-4) and (S)-N-(((S)-9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-cyclopropyl-2-hydroxyacetamide (Compound 2'-4)

[0222] A mixture of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (50 mg, 85.78 μmol, hydrochloride) was dissolved in DMF (1 mL). N,N-Diisopropylethylamine (27.72 mg, 0.21 mmol) was added, and after stirring for 10 minutes, (S)-2-cyclopropyl-2-hydroxyacetic acid (19.92 mg, 0.17 mmol) and HATU (39.12 mg, 0.10 mmol) were added. The reaction system was allowed to react at 25°C for 2 hours. The reaction solution was purified by preparative HPLC and freeze-dried to obtain the title compound 2-4 (29 mg, 52.73 μmol) and compound 2'-4 (2.5 mg, 4.50 μmol).

[0223] The structural characterization data of compound 2-4 are as follows:

[0224] MS m / z(ESI):528.2[M+H] +

[0225] 1 H NMR (400MHz, DMSO) δ8.80(d,J=8.0Hz,1H),8.75(t,J=5.6Hz,1H),8.19(d,J=10.4Hz,1H),7.34(s,1H),6.55(s,1H),5.53(d,J=3.2Hz,2H),5.45(s ,2H),4.88-4.78(m,2H),3.57(d,J=5.6Hz,1H),1.92-1.81(m,2H),1.03- 0.95(m,1H),0.87(t,J=7.6Hz,3H),0.36-0.29(m,2H),0.27-0.20(m,2H).

[0226] The structural characterization data of compound 2'-4 are as follows:

[0227] MS m / z(ESI):528.2[M+H] +

[0228] 1H NMR (400MHz, DMSO) δ8.31(t,J=5.6Hz,1H),8.10-8.01(m,2H),7.35(s,1H),6.56(s,1H),5.55(s,1H),5.45(s,2H),4.93-4.87(m,1H),3.5 3(d,J=6.4Hz,1H),1.93-1.80(m,3H),1.27-1.22(m,1H),1.02-0.97(m,1H),0.87(t,J=7.2Hz,3H),0.36-0.30(m,2H),0.28-0.23(m,2H).

[0229] The preparation method is as follows:

[0230] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0231] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0232] Example 3: Preparation of (R)-N-(((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-cyclopropyl-2-hydroxyacetamide (Compound 2-5) and (R)-N-(((S)-9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-cyclopropyl-2-hydroxyacetamide (Compound 2'-5)

[0233] A mixture of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-4) and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-4) (625 mg, The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was prepared by HPLC and freeze-dried to give the title compounds 2-5 (40 mg, 74.25 μmol) and 2'-5 (3 mg, 5.57 μmol).

[0234] The structural characterization data of compound 2-5 are as follows:

[0235] MS m / z(ESI):530.1[M+H] +

[0236] 1H NMR (400MHz, DMSO-d6) δ8.78(d,J=8.0Hz,1H),8.74(t,J=6.0Hz,1H),8.17(d,J=10.0 Hz,1H),7.33(s,1H),6.55(s,1H),5.55(d,J=5.2Hz,2H),5.51(s,2H),5.44(s,2H),4.88-4.72(m,2H),3.60-3 .53(m,1H),1.92-1.81(m,2H),1.02-0.92(m,1H),0.87(t,J=7.2Hz,3H),0.36-0.28(m,2H),0.26-0.17(m,2H).

[0237] The structural characterization data of compound 2'-5 are as follows:

[0238] MS m / z(ESI):530.2[M+H] +

[0239] 1H NMR(400MHz,DMSO-d6)δ8.35-8.25(m,1H),8.13-7.99(m,2H),7.35(s,1H),6.56(s,1H),5.54(s,2H),5.49-5.41(m, 3H), 4.90 (s, 2H), 3.58-3.50 (m, 1H), 1.95-1.79 (m, 2H), 1.05-0.95 (m, 1H), 0.87 (t, J = 6.4Hz, 3H), 0.40-0.20 (m, 4H).

[0240] The preparation method is as follows:

[0241] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0242] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0243] Example 4: Preparation of (R)-N-(((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (Compound 2-7) and (R)-N-(((S)-9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (Compound 2'-7)

[0244] A mixture of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-4) and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-4) was prepared. 875 mg, 1.50 mmol, hydrochloride, purity 80%), (R)-3-hydroxybutyric acid (312.57 mg, 3.00 mmol), HATU (1.14 g, 3.00 mmol) and DIPEA (970.09 mg, 7.51 mmol) were added to a DMF (15 mL) reaction system and stirred at 25 ° C for 2 hours. The reaction solution was prepared by HPLC and freeze-dried to give the title compounds 2-7 (54 mg, 102.57 μmol) and 2'-7 (10 mg, 19 μmol).

[0245] The structural characterization data of compound 2-7 are as follows:

[0246] ESI-MS (m / z): 516.2 [M+H] + .

[0247] 1 H NMR (400MHz, DMSO) δ8.76-8.66(m,2H),8.18(d,J=10.4Hz,1H),7.34(s,1H),6.56(s,1H),5.55-5.35(m,4H),4.90-4.75(m,2 H),3.98-3.88(m,1H),2.27-2.19(m,1H),2.15-2.08(m,1H),1.93-1.78(m,2H),0.98(d,J=6.0Hz,3H),0.87(t,J=7.2Hz,3H).

[0248] The structural characterization data of compound 2'-7 are as follows:

[0249] ESI-MS (m / z): 516.1 [M+H] + .

[0250] 1H NMR (400MHz, DMSO) δ8.52(t,J=5.6Hz,1H),8.09(d,J=9.6Hz,1H),8.06-8.00(m,1H),7.35(s,1H),6.57(s,1H),5.56-5.42(m,4H),4.87-4.81( m,2H),4.62(br,1H),3.96-3.86(m,1H),2.29-2.21(m,1H),2.19-2.12( m,1H),1.92-1.80(m,2H),0.97(d,J=6.0Hz,3H),0.87(t,J=7.2Hz,3H).

[0251] The preparation method is as follows:

[0252] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0253] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0254] Example 5: (S)-N-(((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (Compound 2-8) and (S)-N-(((S)-9-chloro-4-ethyl-10-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (Compound 2'-8)

[0255] A mixture of (S)-9-chloro-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2-1-4) and (S)-9-chloro-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (compound 2'-1-4) (400 mg, 600.49 μmol, hydrochloride) was added. ) and (S)-3-hydroxybutyric acid (156.3 mg, 1.50 mmol) were dissolved in DMF (6 mL), HATU (456.61 mg, 1.20 mmol) and DIPEA (310.4 mg, 2.40 mmol) were added, and the mixture was reacted at 25°C for 1 hour. Water (20 ml) was added to the system, and the product was extracted with dichloromethane (30 ml*2). The product was washed with 0.5N hydrochloric acid (10 ml) and brine (10 ml) in sequence and concentrated to obtain a crude product. The crude product was purified by preparative HPLC and freeze-dried to obtain the title compounds 2-8 (32.0 mg) and 2'-8 (3.5 mg).

[0256] The structural characterization data of compound 2-8 are as follows:

[0257] MS m / z(ESI):516.1[M+H] +

[0258] 1 H NMR (400MHz, DMSO-d6) δ8.75-8.66(m,2H),8.19(d,J=10.4Hz,1H),7.34(s,1H),6.55(s,1H),5.49(s,2H),5.44(s,2H),4.82(d,J=5.6Hz,2H),4 .61(d,J=4.8Hz,1H),3.96-3.90(m,1H),2.25-2.20(m,1H),2.14-2.09( m,1H),1.92-1.81(m,2H),0.99(d,J=6.0Hz,3H),0.87(t,J=7.2Hz,3H).

[0259] The structural characterization data of compound 2'-8 are as follows:

[0260] MS m / z(ESI):516.1[M+H] +

[0261] 1H NMR (400MHz, DMSO-d6) δ8.51(t,J=5.6Hz,1H),8.11-8.00(m,2H),7.34(s,1H),6.56(s,1H),5.54(s,2H),5.45(s,2H),4.84(d,J= 2.4Hz,2H),4.58(br,1H),3.96-3.87(m,1H),2.28-2.12(m,2H),1.92-1.81(m,2H),0.97(d,J=6.4Hz,3H),0.87(t,J=7.2Hz,3H).

[0262] The preparation method is as follows:

[0263] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0264] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0265] Example 6: N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxyacetamide (Compound 2-9) and N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxyacetamide (Compound 2-10)

[0266] Step 1: Preparation of 1-(2-amino-5-chloro-4-fluorophenyl)-2-chloropropan-1-one (Compound 2-9-2)

[0267] 4-Chloro-3-fluoroaniline (7.00 g, 48.09 mmol) was added to a 1,2-dichloroethane (105 mL) solution and cooled in an ice-water bath for 10 minutes. Boron trichloride (1 M in DCM, 72.13 mmol, 72.13 mL) was then added dropwise to the reaction system and stirred for 30 minutes. 2-Chloropropionitrile (6.46 g, 72.13 mmol) and titanium tetrachloride (13.68 g, 72.13 mmol) were then added in sequence. The temperature was raised to reflux for 16 hours. After the reaction solution was cooled to room temperature, it was added to a 3N aqueous hydrochloric acid solution (105 mL) and heated to 95°C again for 1 hour. After the reaction solution was cooled to room temperature, water and dichloromethane were added for extraction. The combined organic phases were concentrated to give the crude product, which was purified by column chromatography (EA / PE = 0-30%) and concentrated again to give the title compound (6.6 g, 25.16 mmol).

[0268] Its structural characterization data are as follows:

[0269] ESI-MS (m / z): 236.1 [M+H]+.

[0270] 1H NMR (400MHz, DMSO-d6) δ8.05(d,J=8.4Hz,1H),7.66(s,1H),6.78(d,J=12.0Hz,1H),5.76(q,J=6.4Hz,1H),1.59(d,J=6.4Hz,3H)

[0271] Step 2: Preparation of 1-(2-amino-5-chloro-4-fluorophenyl)-2-azidopropan-1-one (Compound 2-9-3)

[0272] 1-(2-Amino-5-chloro-4-fluorophenyl)-2-chloropropan-1-one (3.0 g, 12.71 mmol) was added to DMF (15 mL), and then sodium azide (867.46 mg, 13.34 mmol) was added to the reaction solution. The reaction was carried out at 25°C for 2 hours. Water and MTBE were added to the reaction solution, extracted, and concentrated to obtain the title compound (3.08 g, 12.69 mmol), which was used directly in the next reaction.

[0273] Its structural characterization data are as follows:

[0274] ESI-MS (m / z): 243.0 [M+H] +.

[0275] Step 3: Preparation of 2-amino-1-(2-amino-5-chloro-4-fluorophenyl)propan-1-one (Compound 2-9-4)

[0276] 1-(2-Amino-5-chloro-4-fluorophenyl)-2-azidopropan-1-one (3.08 g, 12.69 mmol) was dissolved in THF (120 mL) and water (40 mL), and triphenylphosphine (4.99 g, 19.04 mmol) was added. The reaction solution was reacted at 25°C for 18 hours. The pH of the reaction solution was adjusted to about 3 with 1.5N aqueous hydrochloric acid solution. Water and ethyl acetate were added, and triphenylphosphine and triphenylphosphine oxide were extracted to remove the product as hydrochloride in the aqueous phase to obtain the title compound (3.21 g, 12.68 mmol), which was directly used in the next reaction.

[0277] Its structural characterization data are as follows:

[0278] ESI-MS (m / z): 217.1 [M+H]+.

[0279] Step 4: Preparation of (9H-fluoren-9-yl)methyl N-(1-(2-amino-5-chloro-4-fluorophenyl)-1-oxopropan-2-yl)carbamate (Compound 2-9-5)

[0280] 2-Amino-1-(2-amino-5-chloro-4-fluorophenyl)propan-1-one (3.21 g, 12.68 mmol) was dissolved in 1,4-dioxane (100 mL) and water (100 mL). Sodium bicarbonate (5.33 g, 63.41 mmol) and Fmoc-OSU (6.42 g, 19.02 mmol) were added sequentially. The reaction solution was reacted at 25°C for 5 hours. Water and ethyl acetate were added, extracted, and concentrated to obtain a crude product, which was purified by preparative HPLC and freeze-dried to obtain the title compound (3.50 g, 7.97 mmol).

[0281] Its structural characterization data are as follows:

[0282] MS m / z(ESI):439.1[M+H]+

[0283] The preparation method is as follows:

[0284] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0285] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0286] Step 5: Preparation of (9H-fluoren-9-yl)methyl N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)carbamate and (9H-fluoren-9-yl)methyl N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)carbamate (Compound 2-9-6)

[0287] (9H-Fluoren-9-yl)methyl N-(1-(2-amino-5-chloro-4-fluorophenyl)-1-oxopropan-2-yl)carbamate (3.00 g, 6.84 mmol), (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (2.70 g, 10.25 mmol), acetic acid (2.46 g, 41.01 mmol) and p-toluenesulfonic acid monohydrate (130.03 mg, 683.56 μmol) were added to toluene (90 mL). The reaction solution was reacted at 110° C. for 36 hours and concentrated to obtain a crude product. The crude product was purified by column chromatography (EA / PE = 0-100%) and concentrated again to obtain the title compound (2.08 g, 3.12 mmol).

[0288] Its structural characterization data are as follows:

[0289] MS m / z(ESI):666.2[M+H] +

[0290] Step 6: Preparation of (S)-11-(1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (Compound 2-9-7)

[0291] (9H-fluoren-9-yl)methyl N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)carbamate and (9H-fluoren-9-yl)methyl N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)carbamate were prepared. 4,12,14-Tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)carbamate (2.08 g, 3.12 mmol) was dissolved in DMF (15 mL), and diethylamine (1.14 g, 15.61 mmol) was added. The reaction solution was reacted at 25°C for 1 hour, concentrated to give a crude product, slurried with MTBE, filtered, and the filter cake was collected and dried to give the title compound (1.15 g, 2.49 mmol).

[0292] Its structural characterization data are as follows:

[0293] MS m / z(ESI):444.1[M+H] +

[0294] Step 7: Preparation of (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (Compound 2-9-7A) and (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (Compound 2-9-7B)

[0295] (S)-11-(1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1.00 g, 2.25 mmol) was dissolved in MeOH (50 mL), and EA / HCl (10 mL) was added. The reaction solution was reacted at 25°C for 1.5 hours, concentrated to give a crude product, and purified by preparative HPLC and freeze-dried to give the title compound (2-9-7A) (390 mg, 685.10 μmol, trifluoroacetate salt) with a retention time of t = 1.447 min, and compound (2-9-7B) (417 mg, 732.53 μmol, trifluoroacetate salt) with a retention time of t = 1.503 min.

[0296] The structural characterization data of compound 2-9-7A are as follows:

[0297] MS m / z(ESI):444.1[M+H] +

[0298] 1 H NMR(400MHz,DMSO-d6)δ8.81(d,J=7.6Hz,1H),8.56(br,3H),8.29(d,J=10.0Hz,1H),7.38(s,1H) ,6.60(s,1H),5.72-5.40(m,5H),1.95-1.81(m,2H),1.75(d,J=7.2Hz,3H),0.87(t,J=7.2Hz,3H).

[0299] The structural characterization data of compound 2-9-7B are as follows:

[0300] MS m / z(ESI):444.1[M+H] +

[0301] 1 H NMR(400MHz,DMSO-d6)δ8.81(d,J=8.0Hz,1H),8.60(br,3H),8.29(d,J=10.0Hz,1H),7.39(s,1H) ,6.60(s,1H),5.70-5.40(m,5H),1.94-1.80(m,2H),1.74(d,J=6.8Hz,3H),0.87(t,J=7.2Hz,3H).

[0302] The preparation method is as follows:

[0303] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0304] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% trifluoroacetic acid)

[0305] Step 8: Preparation of N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxyacetamide (Compound 2-9)

[0306] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (2-9-7A, 40.00 mg, 71.70 μmol, trifluoroacetate) and DIPEA (46.33 mg, 358.50 μmol) were dissolved in DMF (3 mL) and stirred at 25°C for 20 min. Glycolic acid (10.91 mg, 143.40 μmol) and HATU (54.53 mg, 143.40 μmol) were added sequentially, and the reaction system was reacted at 25°C for 1.5 hours. The reaction solution was purified by preparative HPLC and lyophilized to obtain the title compound (25 mg, 48.82 μmol).

[0307] Its structural characterization data are as follows:

[0308] MS m / z(ESI):502.1[M+H] +

[0309] 1 H NMR (400MHz, DMSO-d6) δ8.88-8.82(m,2H),8.19(d,J=10.4Hz,1H),7.33(s,1H),6.56(s,1H),5.80-5.70(m,1H),5.52(d,J=19.2 Hz,1H),5.44(s,2H),5.33(d,J=19.2Hz,1H),3.94-3.83(m,2H),1.93-1.77(m,2H),1.59(d,J=7.2Hz,3H),0.86(t,J=7.2Hz,3H).

[0310] The preparation method is as follows:

[0311] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0312] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% trifluoroacetic acid)

[0313] Step 9: Preparation of N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxyacetamide (Compound 2-10)

[0314] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (2-9-7B, 35.00 mg, 62.74 μmol, trifluoroacetate) and DIPEA (40.54 mg, 313.69 μmol) were dissolved in DMF (3 mL) and stirred at 25°C for 20 min. Glycolic acid (9.54 mg, 125.48 μmol) and HATU (47.71 mg, 125.48 μmol) were then added sequentially. The reaction system was reacted at 25°C for 1.5 hours. The reaction solution was purified by preparative HPLC and lyophilized to obtain the title compound (12 mg, 23.43 μmol).

[0315] Its structural characterization data are as follows:

[0316] MS m / z(ESI):502.1[M+H]

[0317] 1 H NMR (400MHz, DMSO-d6) δ8.88-8.82(m,2H),8.20(d,J=10.4Hz,1H),7.34(s,1H),6.56(s,1H),5.80-5.70(m,1H),5.58-5.50(m ,2H),5.44(s,2H),5.32(d,J=19.2Hz,1H),3.94-3.85(m,2H),1.93-1.78(m,2H),1.58(d,J=7.2Hz,3H),0.86(t,J=7.2Hz,3H).

[0318] The preparation method is as follows:

[0319] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0320] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0321] Example 7: (S)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxypropionamide (2-11)

[0322] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, trifluoroacetate) was added to DMF (2 mL), followed by DIPEA (34.75 mg, 268.88 μmol). The reaction was stirred at 22°C for 20 minutes. Finally, (S)-2-hydroxypropionic acid (9.69 mg, 107.55 μmol) was added, and the reaction was stirred at 22°C for 1 hour. The reaction solution was purified by HPLC and freeze-dried to obtain the title compound (17.15 mg, 32.91 μmol).

[0323] Its structural characterization data are as follows:

[0324] MS m / z(ESI):516.2[M+H] +

[0325] 1 H NMR (400MHz, DMSO) δ8.83(d,J=8.0Hz,1H),8.80(d,J=5.5Hz,1H),8.19(d,J=10.2Hz,1H),7.34(s,1H),6.56(s,1H),5.75-5.67(m,1H), 5.58(d,J=4.9Hz,1H),5.57-5.29(m,4H),4.08(m,1H),1.86(m,1H),1.58(d,J=7.2Hz,3H),1.16(d,J=6.7Hz,3H),0.87(t,J=7.3Hz,3H).

[0326] The preparation method is as follows:

[0327] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0328] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0329] Example 8: (S)-N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxypropionamide (2-12)

[0330] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (35 mg, 78.85 μmol, trifluoroacetate) was added to DMF (2 mL), followed by DIPEA (50.96 mg, 157.71 μmol). The reaction was stirred at 22°C for 20 minutes. Finally, (S)-2-hydroxypropionic acid (14.21 mg, 157.71 μmol) was added, and the reaction was stirred at 22°C for 1 hour. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (22.76 mg, 42.35 μmol).

[0331] Its structural characterization data are as follows:

[0332] MS m / z(ESI):516.2[M+H] +

[0333] 1 H NMR (400MHz, DMSO) δ8.84(d,J=8.0Hz,1H),8.80(d,J=5.8Hz,1H),8.19(d,J=10.2Hz,1H),7.33(s,1H),5.77-5.68(m,1H),5.5 8-5.32(m,4H),4.03(q,J=6.7Hz,1H),1.95-1.75(m,2H),1.58(d,J=7.2Hz,3H),1.22(d,J=6.7Hz,3H),0.86(t,J=7.3Hz,3H).

[0334] The preparation method is as follows:

[0335] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0336] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0337] Example 9: (R)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxypropionamide (2-13)

[0338] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (35 mg, 0.08 mmol, purity 80%), (R)-2-hydroxypropionic acid (90 mg, 0.01 mmol), HATU (50.96 mg, 0.39 mmol) and DIPEA (59.97 mg, 0.16 mmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 1 hour. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (22 mg, 41.79 μmol).

[0339] Its structural characterization data are as follows:

[0340] MS m / z(ESI):516.2[M+H] +

[0341] 1 H NMR(400MHz,DMSO-d6)δ8.82(t,J=6.4Hz,2H),8.20(d,J=10.2Hz,1H),7.34 (s,1H),6.55(s,1H),5.74-5.69(m,2H),5.44(s,2H),4.08(d,J=6.6Hz,1H), 2.00(dd,J=14.4,6.9Hz,1H),1.86(dt,J=14.2,6.8Hz,3H),1.57(d,J=7.2Hz ,3H),1.51-1.40(m,2H),1.16(d,J=6.6Hz,3H),0.86(dd,J=9.2,5.2Hz,4H).

[0342] The preparation method is as follows:

[0343] Column: SunFire Prep C18 OBD (5μm*19mm*150mm)

[0344] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0345] Example 10: (R)-N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-hydroxypropionamide (2-14)

[0346] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (40 mg, 0.09 mmol, purity 80%), (R)-2-hydroxypropionic acid (16.24 mg, 0.18 mmol), HATU (68.53 mg, 0.18 mmol) and DIPEA (58.24 mg, 0.45 mmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 1 hour. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (25 mg, 47.49 μmol).

[0347] Its structural characterization data are as follows:

[0348] MS m / z(ESI):516.2[M+H] +

[0349] 1 H NMR (400MHz, DMSO) δ8.85(d,J=8.0Hz,0H),8.80(d,J=5.6Hz,2H),8.20(d,J=10.2Hz,1H),7.33(s,1H),5.75-5.69(m,1H),5.56-5.33(m,5H),4 .05-4.00(m,1H),1.86(ddd,J=24.8,14.0,7.3Hz,3H),1.59(d,J=7.2Hz,3H),1.53-1.40(m,2H),1.22(d,J=6.8Hz,4H),0.86(t,J=7.2Hz,3H).

[0350] The preparation method is as follows:

[0351] Column: SunFire Prep C18 OBD (5μm*19mm*150mm)

[0352] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0353] Preparation Example 11: (S)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-cyclopropyl-2-hydroxyacetamide (2-15)

[0354] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, trifluoroacetate), (S)-2-cyclopropyl-2-hydroxyacetic acid (12.49 mg, 107.55 μmol), HATU (40.87 mg, 107.55 μmol) and DIPEA (34.75 mg, 268.88 μmol) were added to a DMF (10 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (20 mg, 36.53 μmol).

[0355] Its structural characterization data are as follows:

[0356] MS m / z(ESI):542.1[M+H] +

[0357] 1 H NMR (400MHz, DMSO) δ8.85(d,J=8.0Hz,1H),8.75(d,J=5.2Hz,1H),8.19(d,J=10.0Hz,1H),7.33(s,1H),6.55(s,1H),5.74-5.65(m,1H),5.54-5.35 (m,5H),3.60(t,J=5.6Hz,1H),3.31(s,1H),1.92-1.80(m,2H),1.58(d,J =7.2Hz,3H),1.01-0.96(m,1H),0.86(t,J=7.6Hz,3H),0.39-0.23(m,4H).

[0358] The preparation method is as follows:

[0359] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0360] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0361] Preparation Example 12: (S)-N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-cyclopropyl-2-hydroxyacetamide (2-16)

[0362] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, trifluoroacetate), (S)-2-cyclopropyl-2-hydroxyacetic acid (12.49 mg, 107.55 μmol), HATU (40.87 mg, 107.55 μmol) and DIPEA (34.75 mg, 268.88 μmol) were added to a DMF (10 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (16 mg, 28.93 μmol).

[0363] Its structural characterization data are as follows:

[0364] MS m / z(ESI):542.1[M+H] +

[0365] 1 H NMR (400MHz, DMSO) δ8.85(d,J=8.0Hz,1H),8.78(d,J=5.6Hz,1H),8.19(dd, J=1.6,10.4Hz,1H),7.33(s,1H),6.55(s,1H),5.78-5.70(m,1H),5.53-5.40 (m,5H),3.49(t,J=6.0Hz,1H),3.31-3.29(m,1H),1.91-1.80(m,2H),1.58(d ,J=7.2Hz,3H),1.04-0.98(m,1H),0.86(t,J=7.2Hz,3H),0.44-0.28(m,4H).

[0366] The preparation method is as follows:

[0367] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0368] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0369] Example 13: (R)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-cyclopropyl-2-hydroxyacetamide (2-17)

[0370] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, purity 80%), (2R)-2-cyclopropyl-2-hydroxy-acetic acid (12.02 mg, 107.55 μmol), HATU (40.87 mg, 107.5 μmol) and DIPEA (34.75 mg, 268.88 μmol) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (17 mg, 31.05 μmol).

[0371] Its structural characterization data are as follows:

[0372] MS m / z(ESI):542.2[M+H] +

[0373] 1 H NMR(400MHz, DMSO-d6)δ8.85(d,J=8.0Hz,1H),8.78(t,J=5.2Hz,1H),8.19( d,J=10.4Hz,1H),7.34(s,1H),6.56(s,1H),5.72(t,J=6.8Hz,1H),5.47-5. 41(m,4H),3.48-3.46(m,1H),1.92-1.81(m,2H),1.59(d,J=7.2Hz,3H),1.0 2-0.92(m,1H),0.87(t,J=7.2Hz,3H),0.36-0.28(m,2H),0.26-0.17(m,2H)

[0374] The preparation method is as follows:

[0375] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0376] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0377] Example 14: (R)-N-((R)-1-((S) -9-Chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-2-cyclopropyl-2-hydroxyacetamide (2-18)

[0378] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (40 mg, 71.70 μmol, purity 80%), (2R)-2-cyclopropyl-2-hydroxy-acetic acid (16.65 mg, 143.4 μmol), HATU (54.52 mg, 143.4 μmol) and DIPEA (46.33 mg, 358.5 μmol) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly prepared by HPLC and freeze-dried to obtain the title compound (23.6 mg, 41.37 μmol).

[0379] Its structural characterization data are as follows:

[0380] MS m / z(ESI):542.2[M+H] +

[0381] 1 H NMR(400MHz,DMSO-d6)δ8.85(d,J=8.0Hz,1H),8.77(t,J=5.6Hz,1H),8.20( d,J=10.4Hz,1H),7.34(s,1H),6.56(s,1H),5.70(t,J=6.8Hz,1H),5.55-5.3 5(m,4H),3.61(t,J=4.2Hz,1H),1.91-1.78(m,2H),1.59(d,J=6.4Hz,3H),1. 02-0.95(m,1H),0.86(t,J=7.6Hz,3H),0.36-0.28(m,2H),0.26-0.17(m,2H)

[0382] The preparation method is as follows:

[0383] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0384] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0385] Example 15: (R)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-3-hydroxybutanamide (2-21)

[0386] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, purity 95%), (R)-3-hydroxybutyric acid (11.20 mg, 107.55 μmol), HATU (40.89 mg, 107.55 μmol) and DIPEA (34.75 mg, 268.88 μmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (25 mg, 44.82 μmol).

[0387] Its structural characterization data are as follows:

[0388] MS m / z(ESI):530.2[M+H] +

[0389] 1 H NMR (400MHz, DMSO-d6) δ8.89(d,J=4.8Hz,1H),8.80(d,J=8.0Hz,1H),8.19(d,J=10 .4Hz,1H),7.33(s,1H),6.55(s,1H),5.71(s,1H),5.58(d,J=19.2Hz,1H),5.44-5. 35(m,3H),3.90-3.86(m,1H),2.35-2.31(m,1H),2.19(dd,J=13.6,4.8Hz,1H),1.9 3-1.80(m,2H),1.49(d,J=7.2Hz,3H),1.04(d,J=6.0Hz,3H),0.86(t,J=7.2Hz,3H).

[0390] The preparation method is as follows:

[0391] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0392] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0393] Example 16: (R)-N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-3-hydroxybutanamide (2-22)

[0394] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30 mg, 53.78 μmol, purity 95%), (R)-3-hydroxybutyric acid (11.20 mg, 107.55 μmol), HATU (40.89 mg, 107.55 μmol) and DIPEA (34.75 mg, 268.88 μmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (19 mg, 34.06 μmol).

[0395] Its structural characterization data are as follows:

[0396] MS m / z(ESI):530.1[M+H] +

[0397] 1 H NMR (400MHz, DMSO-d6) δ8.89(d,J=4.8Hz,1H),8.80(d,J=8.0Hz,1H),8.19(d,J=10. 0Hz,1H),7.33(s,1H),6.56(s,1H),5.68-5.64(m,1H),5.46-5.41(m,3H),5.32(d,J= 19.2Hz,1H),3.94-3.90(m,1H),2.35-2.31(m,1H),2.21(dd,J=13.6,5.6Hz,1H),1. 93-1.78(m,2H),1.52(d,J=7.2Hz,3H),0.96(d,J=6.4Hz,3H),0.86(t,J=7.2Hz,3H).

[0398] The preparation method is as follows:

[0399] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0400] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0401] Example 17: (S)-N-((S)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-3-hydroxybutanamide (2-23)

[0402] (S)-11-((S)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30.0 mg, 53.8 μmol, trifluoroacetate) and DIPEA (27.8 mg, 215.1 μmol) were added sequentially to DMF (1 mL) and stirred for 5 minutes. (S)-3-hydroxybutyric acid (11.2 mg, 107.6 μmol) and HATU (40.9 mg, 107.6 μmol) were added and reacted at 25°C for 1 hour. The reaction solution was directly purified by preparative HPLC and freeze-dried to give the title compound (20.0 mg, 36.61 μmol).

[0403] Its structural characterization data are as follows:

[0404] MS m / z(ESI):530.2[M+H] +

[0405] 1 H NMR (400MHz, DMSO-d6) δ8.88(d,J=5.2Hz,1H),8.80(d,J=8.0Hz,1H),8.19(d,J=1 0.2Hz,1H),7.33(s,1H),6.56(br,1H),5.65-5.62(m,1H),5.44-5.40(m,3H),5.31 (d,J=19.2Hz,1H),3.95-3.90(m,1H),2.36-2.30(m,1H),2.23-2.18(m,1H),1.91 -1.80(m,2H),1.53(d,J=7.2Hz,3H),0.97(d,J=6.0Hz,3H),0.86(t,J=7.2Hz,3H).

[0406] The preparation method is as follows:

[0407] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0408] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0409] Example 18: (S)-N-((R)-1-((S)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)ethyl)-3-hydroxybutanamide (2-24)

[0410] (S)-11-((R)-1-aminoethyl)-9-chloro-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (30.0 mg, 53.8 μmol, trifluoroacetate) and DIPEA (27.8 mg, 215.1 μmol) were added sequentially to DMF (1 mL) and stirred for 5 minutes. (S)-3-hydroxybutyric acid (11.2 mg, 107.6 μmol) and HATU (40.9 mg, 107.6 μmol) were added and reacted at 25°C for 1 hour. The reaction solution was directly purified by preparative HPLC and freeze-dried to give the title compound (15.0 mg, 27.46 μmol).

[0411] Its structural characterization data are as follows:

[0412] MS m / z(ESI):530.1[M+H] +

[0413] 1 H NMR (400MHz, DMSO-d6) δ8.89(d,J=4.0Hz,1H),8.79(d,J=7.6Hz,1H),8.18(d,J=10.0 Hz,1H),7.32(s,1H),6.55(s,1H),5.71-5.66(m,1H),5.59(d,J=19.2Hz,1H),5.43(s,2H),5.37(d,J=19.2Hz,1H),4.60(br,1H),3.93 -3.83(m,1H),2.37(m,1H),2.20-2.17(m,1H),1.91-1.76(m,2H),1.49(d,J=6.8Hz,3H),1.04(d,J=5.6Hz,3H),0.86(t,J=6.8Hz,3H).

[0414] The preparation method is as follows:

[0415] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0416] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0417] Example 19: (S)-2-cyclopropyl-N-(((S)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (1-3)

[0418] Step 1: Preparation of 1-(2-amino-4-fluoro-5-methylphenyl)-2-chloroethane-1-one (1-3-2A) and 1-(6-amino-2-fluoro-3-methylphenyl)-2-chloroethane-1-one (1-3-2B)

[0419] Under nitrogen, add 3-fluoro-4-methylaniline (20 g, 159.82 mmol) to 1,2-dichloroethane (400 mL) and cool in an ice-water bath for 10 minutes. Add boron trichloride (207.76 mL, 1 M) dropwise to the reaction system and stir for 30 minutes. Add 2-chloroacetonitrile (14.48 g, 191.78 mmol) and titanium tetrachloride (45.47 g, 239.73 mmol) sequentially to the reaction system. Remove from the ice-water bath and heat to reflux for 16 hours. Pour the reaction solution into 3N hydrochloric acid (60 mL), heat to reflux, and react for 1 hour. After the reaction is complete, cool to room temperature, add dichloromethane (150 mL), and stir for 5 minutes. Separate the lower organic phase, extract the aqueous phase once with dichloromethane (200 mL), combine the organic phases, and concentrate to yield a brown crude product. The crude product was purified by silica gel column chromatography to give a mixture of the title compounds (20 g, 89.27 mmol).

[0420] Step 2: Preparation of a mixture of (S)-11-(chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-3A) and (S)-11-(chloromethyl)-4-ethyl-10-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-3B).

[0421] A mixture of 1-(2-amino-4-fluoro-5-methylphenyl)-2-chloroethane-1-one and 1-(6-amino-2-fluoro-3-methylphenyl)-2-chloroethane-1-one (14.2 g, 70.43 mmol) was dissolved in toluene (10 mL), and (4S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10-trione (19.47 g, 73.9 5mmol), p-toluenesulfonic acid monohydrate (6.70g, 35.21mmol), stirred for 5 minutes, if not dissolved and clarified, heated to 110℃ and refluxed for 6 hours (heated to 90-100℃ to dissolve and clarify, and then a large amount of solid precipitated). After the reaction is completed, cooled to 50-60℃, methanol (120ml) was added, stirred and cooled to room temperature, filtered and dried to obtain a mixture of the title compound (21.16g, 34.54mmol).

[0422] Step 3: Preparation of (S)-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-4A) and (S)-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-4B).

[0423] A mixture of (S)-11-(chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione and (S)-11-(chloromethyl)-4-ethyl-10-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (2 g, 4.66 mmol) was suspended in EtOH (30 mL), and hexamethylenetetramine (1.96 g, 13.99 mmol) was added. The mixture was heated to 80-85°C and refluxed for 4 hours. After the reaction is complete, cool to 40-50°C and add 50 ml of concentrated hydrochloric acid dropwise. A slight exotherm will occur, and the mixture is stirred at 40-50°C for 0.5 hours. Methyl tert-butyl ether (300 ml) is added and stirred for 2 hours. Solids precipitate, which are filtered and dried to obtain 4 g of a crude product. This crude product is purified via reverse-phase column chromatography to yield 440 mg of the mixture. The mixture was purified by preparative method to give (S)-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-4A) (145 mg, 336.46 μmol) and (S)-11-(aminomethyl)-4-ethyl-10-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (1-3-4B) (55 mg, 127.62 μmol).

[0424] The structural characterization data of compounds 1-3-4A and 1-3-4B are as follows:

[0425] MS m / z (ESI) of compound 1-3-4A: 410.2 [M+H] +

[0426] MS m / z (ESI) of compound 1-3-4B: 410.2 [M+H] +

[0427] The preparation method is as follows:

[0428] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0429] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% trifluoroacetic acid)

[0430] Step 4: Preparation of (S)-2-cyclopropyl-N-(((S)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (1-3)

[0431] (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (25 mg, 54.89 μmol, formate), (S)-2-cyclopropyl-2-hydroxyacetic acid (11.09 mg, 95.52 μmol), HATU (36.32 mg, 95.52 μmol) and DIPEA (30.86 mg, 238.81 μmol) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (14 mg, 26.21 μmol).

[0432] Its structural characterization data are as follows:

[0433] MS m / z(ESI):508.3[M+H] +

[0434] 1 H NMR (400MHz, DMSO) δ8.66(t,J=5.6Hz,1H),8.42(d,J=8.4Hz,1H),7.89(d,J=10.8Hz,1H),7.31(s,1H),6.53(s,1H),5.53(d,J=5.2Hz,1H),5.49(s,1 H),5.43(s,2H),4.89-4.76(m,2H),3.58-3.55(m,1H),3.31(s,2H),1.92- 1.80(m,2H),1.05-0.97(m,1H),0.87(t,J=7.2Hz,3H),0.37-0.21(m,4H).

[0435] The high performance liquid chromatography preparation method is as follows:

[0436] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0437] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0438] Example 20: (R)-2-cyclopropyl-N-(((S)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (1-4)

[0439] (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (25 mg, 54.89 μmol, formate), (R)-2-cyclopropyl-2-hydroxyacetic acid (11.09 mg, 95.52 μmol), HATU (36.32 mg, 95.52 μmol) and DIPEA (30.86 mg, 238.81 μmol) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly prepared by HPLC and freeze-dried to obtain the title compound (20.1 mg, 24.24 μmol).

[0440] Its structural characterization data are as follows:

[0441] MS m / z(ESI):508.5[M+H] +

[0442] 1 H NMR (400MHz, DMSO-d6) δ8.66(t,J=6.0Hz,1H),8.33(d,J=8.4Hz,1H),7.90(d,J= 10.8Hz,1H),7.32(s,1H),6.53(s,1H),5.30(d,J=5.2Hz,1H),5.50(s,2H),5.44 (s,2H),4.90-4.78(m,2H),3.57(t,J=5.6Hz,1H),2.54(s,3H),1.92-1.81(m,2H ),1.04-0.96(m,1H),0.87(t,J=7.2Hz,3H),0.36-0.31(m,2H),0.27-0.21(m,2H)

[0443] The preparation method is as follows:

[0444] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0445] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0446] Example 21: (R)-N-(((S)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (1-5)

[0447] (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (25 mg, 61.06 μmol), (R)-3-hydroxybutyric acid (10.28 mg, 98.76 μmol), HATU (37.55 mg, 98.76 μmol) and DIPEA (31.91 mg, 246.89 μmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (10.03 mg, 14.81 μmol).

[0448] Its structural characterization data are as follows:

[0449] MS m / z(ESI):496.2[M+H] +

[0450] 1 H NMR (400MHz, DMSO-d6) δ8.67(t,J=5.6Hz,1H),8.34(d,J=8.4Hz,1H),7.90(d,J=10.8 Hz,1H),7.31(s,1H),6.54(s,1H),5.50-5.40(m,4H),4.82(d,J=5.6Hz,2H),4.64(s,1H),3.92-3.97(m,1H),2. 51(s,3H),2.26-2.21(m,1H),2.15-2.10m,1H),1.92-1.81(m,2H),0.99(d,J=6.0Hz,3H),0.87(t,J=7.2Hz,3H).

[0451] The preparation method is as follows:

[0452] Chromatographic column: Waters SunFire Prep C18OBD (5μm*19mm*150mm)

[0453] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% trifluoroacetic acid)

[0454] Example 22: (S)-N-(((S)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (1-6)

[0455] (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (55.0 mg, 120.76 μmol, formate) and DIPEA (62.43 mg, 483.05 μmol) were added to DMF (2 mL) and stirred for 5 minutes. Then, (S)-3-hydroxybutyric acid (25.14 mg, 241.53 μmol) and HATU (91.99 mg, 241.95 μmol) were added and stirred at 25°C for 1 hour. The reaction solution was directly subjected to HPLC and freeze-dried to obtain 16.0 mg of a white solid, which was then purified by thin layer chromatography (MeOH / DCM = 7%) to obtain the title compound (12.3 mg, 22.34 μmol).

[0456] Its structural characterization data are as follows:

[0457] MS m / z(ESI):496.2[M+H] +

[0458] 1 H NMR (400MHz, DMSO-d6) δ8.68(t,J=5.6Hz,1H),8.35(d,J=8.4Hz,1H),7.90(d,J=10.4Hz,1H),7.31(s,1H),6.54(s ,1H),5.45(s,2H),5.44(s,2H),4.82(d,J=5.6Hz,2H),4.63(d,J=4.0Hz,1H),3.99-3.89(m,1H),2.50(s,3H)2.26 -2.21(m,1H),2.15-2.10(m,1H),1.93-1.79(m,2H),1.00(d,J=6.4Hz,3H),0.87(t,J=7.2Hz,3H).

[0459] The preparation method is as follows:

[0460] Chromatographic column: Waters SunFire Prep C18OBD (5μm*19mm*150mm)

[0461] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0462] Example 23: (S)-2-Cyclopropyl-N-(((S)-4-ethyl-8-chloro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (3-4)

[0463] Step 1: Preparation of 1-(2-amino-4-chloro-5-methylphenyl)-2-chloroethane-1-one (3-4-2A)

[0464] 3-Chloro-4-methylaniline (20 g, 141.25 mmol) was added to DCE (150 mL). After nitrogen protection, the mixture was cooled in an ice bath. Boron trichloride (33.10 g, 282.49 mmol) was added dropwise at 0-10°C. The mixture was stirred for 0.5 h. Chloroacetonitrile (21.33 g, 282.49 mmol) was added. The mixture was heated to reflux and reacted for 20 h. After completion of the reaction, the temperature was lowered to 25°C and the reaction mixture was added to 3N HCl solution (160 mL). The temperature was then raised to reflux and reacted for 4 h. After completion of the reaction, the temperature was lowered to 25°C, water (100 mL) was added, and the mixture was extracted with DCM (100 mL x 2). The organic phase was washed with water, dried, concentrated to dryness, and purified on a silica gel column (ethyl acetate / petroleum ether = 0% to 100%). The mixture was concentrated again to obtain the title compound (1.9 g, 8.71 mmol).

[0465] Its structural characterization is as follows:

[0466] MS m / z(ESI):218.0[M+H] +

[0467] 1 H NMR (400MHz, DMSO): δ7.71 (d, J=0.9Hz, 1H), 7.20 (s, 2H), 6.90 (s, 1H), 5.02 (s, 2H), 2.20 (d, J=0.7Hz, 3H).

[0468] Step 2: Preparation of 1-(2-amino-4-chloro-5-methylphenyl)-2-azidoethane-1-one (3-4-3)

[0469] To DMF (4 mL) were added 1-(2-amino-4-chloro-5-methylphenyl)-2-chloroethane-1-one (927 mg, 4.25 mmol) and sodium azide (290.16 mg, 4.46 mmol). The mixture was stirred at 25 °C for 2 h. After the reaction was complete, water (20 mL) was added and MTBE (10 mL*2) was added for extraction. The organic phase was concentrated to dryness to give the crude title compound (1.1 g), which was used directly in the next step without purification.

[0470] Its structural characterization is as follows:

[0471] MS m / z(ESI):225.1[M+H] +

[0472] Step 3: Preparation of 2-amino-1-(2-amino-4-chloro-5-methylphenyl)ethane-1-one hydrochloride (3-4-4)

[0473] Crude 1-(2-amino-4-chloro-5-methylphenyl)-2-azidoethane-1-one (1.1 g) and triphenylphosphine (1.93 g, 7.34 mmol) were added to THF (18 mL) and 3N HCl solution (6 mL). After the addition, the mixture was stirred at 25°C for 2 h. After the reaction was completed, water (40 mL) was added and impurities were extracted with EA (20 mL*3). The pH of the aqueous phase was adjusted to 8-9 with sodium bicarbonate to give the crude title compound (1.1 g), which was used directly in the next step without purification.

[0474] Step 4: Preparation of (9H-fluoren-9-yl)methyl N-(2-(2-amino-4-chloro-5-methylphenyl)-2-oxoethyl)carbamate (3-4-5):

[0475] 9-Fluorenylmethyl-N-succinimidyl carbonate (3.22 g, 5.61 mmol) was added to the aqueous phase in the previous step. After the addition was complete, the mixture was stirred at 23°C for 3 h. After the reaction was complete, the mixture was extracted with EA (20 mL*2), washed with water, dried, concentrated to dryness, and purified on a silica gel column (ethyl acetate / petroleum ether = 0% to 70%) to obtain the title compound (905 mg, 2.15 mmol).

[0476] Its structural characterization is as follows:

[0477] MS m / z(ESI):421.3[M+H] +

[0478] Step 5: Preparation of (9H-fluoren-9-yl)methyl N-(S)-((8-chloro-4-ethyl-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (3-4-6):

[0479] To toluene (30 mL) were added (9H-fluoren-9-yl)methyl N-(2-(2-amino-4-chloro-5-methylphenyl)-2-oxoethyl)carbamate (905 mg, 2.15 mmol), (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (594.34 mg, 2.26 mmol), acetic acid (774.75 mg, 12.90 mmol), and p-toluenesulfonic acid monohydrate (40.90 mg, 215.02 μmol). After the addition was complete, the temperature was raised to reflux for 20 h. After the reaction was complete, the temperature was lowered to 23 °C, filtered, and the filter cake was dried to give the crude title compound (885 mg).

[0480] Its structural characterization is as follows:

[0481] MS m / z(ESI):648.3[M+H] +

[0482] Step 6: Preparation of (S)-11-(aminomethyl)-8-chloro-4-ethyl-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (3-4-7):

[0483] To DMF (10 mL) were added crude (9H-fluoren-9-yl)methyl N-(S)-((8-chloro-4-ethyl-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (885 mg) and diethylamine (199.74 mg, 2.73 mmol). The mixture was stirred at 23°C for 2 h. After completion of the reaction, the mixture was purified by reverse-phase column chromatography (acetonitrile / aqueous ammonium bicarbonate solution = 0% to 50%) and lyophilized to give the title compound (174 mg, 388.15 μmol).

[0484] Its structural characterization is as follows:

[0485] MS m / z(ESI):426.2[M+H] +

[0486] Step 7: Preparation of (S)-2-cyclopropyl-N-(((S)-4-ethyl-8-chloro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (3-4)

[0487] (S)-11-(Aminomethyl)-8-chloro-4-ethyl-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (25 mg, 58.7 μmol), (S)-2-cyclopropyl-2-hydroxyacetic acid (9.84 mg, 84.77 μmol), HATU (32.23 mg, 84.77 μmolμmol) and DIPEA (32.87 mg, 254.30 μmo) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly purified by HPLC and freeze-dried to obtain the title compound (14 mg, 26.19 μmol).

[0488] Its structural characterization data are as follows:

[0489] MS m / z(ESI):524.2[M+H] +

[0490] 1 H NMR (400MHz, DMSO) δ8.67(t,J=5.6Hz,1H),8.47(s,1H),8.25(s,1H),7.32(s,1H),6.54(s,1H),5.53(d,J=4.8Hz,1H),5.50(s,1H),5.44( s,2H),4.89-4.75(m,2H),3.58-3.54(m,1H),2.58(s,3H),1.95-1.80(s,2H),1.05-0.97(m,1H),0.87(t,J=7.2Hz,3H),0.39-0.22(m,4H).

[0491] The preparation method is as follows:

[0492] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)

[0493] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0494] Example 24: (R)-2-cyclopropyl-N-(((S)-4-ethyl-8-chloro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyacetamide (3-5)

[0495] (S)-11-(Aminomethyl)-8-chloro-4-ethyl-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (20 mg, 46.96 μmol), (R)-2-cyclopropyl-2-hydroxyacetic acid (9.84 mg, 84.77 μmol), HATU (36.32 mg, 95.52 μmol) and DIPEA (27.39 mg, 211.91 μmol) were added to a DMF (2 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly prepared by HPLC and freeze-dried to obtain the title compound (22.2 mg, 28.34 μmol).

[0496] Its structural characterization data are as follows:

[0497] MS m / z(ESI):524.5[M+H] +

[0498] 1 H NMR(400MHz,DMSO-d6)δ8.67(t,J=5.6Hz,1H),8.47(s,1H),8.26(s,1H),7. 32(s,1H),6.55(s,1H),5.54(d,J=4.8Hz,1H),5.50(s,2H),5.44(s,2H),4. 90-4.77(m,2H),3.57(t,J=5.6Hz,1H),2.58(s,3H),1.92-1.81(m,2H),1.0 2-0.95(m,1H),0.87(t,J=7.2Hz,3H),0.36-0.28(m,2H),0.26-0.17(m,2H)

[0499] The preparation method is as follows:

[0500] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)

[0501] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0502] Example 25: (R)-N-(((S)-8-chloro-4-ethyl-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (3-7)

[0503] (S)-11-(Aminomethyl)-8-chloro-4-ethyl-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (25 mg, 58.7 μmol), (R)-3-hydroxybutyric acid (9.71 mg, 93.31 μmol), HATU (35.48 mg, 93.31 μmol) and DIPEA (30.15 mg, 233.28 μmol) were added to a DMF (3 mL) reaction system and stirred at 25°C for 2 hours. The reaction solution was directly prepared by HPLC and freeze-dried to obtain the title compound (12.20 mg, 23.12 μmol).

[0504] Its structural characterization data are as follows:

[0505] MS m / z(ESI):512.2[M+H] +

[0506] 1 H NMR(400MHz,DMSO-d6)δ8.68-8.65(m,1H),8.39(s,1H),8.27(s,1H),7.32(s,1H),6.54(s, 1H),5.46(d,J=3.6Hz,2H),5.44(s,2H),4.82(d,J=5.6Hz,2H),4.63(d,J=4.8,1H),3.98-3.90(m,1H),2.59( s,3H),2.29-2.19(m,1H),2.15-2.10(m,1H),1.93-1.80(m,2H),0.99(d,J=6.4Hz,3H),0.87(t,J=7.2Hz,3H).

[0507] The preparation method is as follows:

[0508] Chromatographic column: Waters SunFire Prep C18OBD (5μm*19mm*150mm)

[0509] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)

[0510] Example 26: (S)-N-(((S)-8-chloro-4-ethyl-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-hydroxybutanamide (3-8)

[0511] (S)-11-(Aminomethyl)-8-chloro-4-ethyl-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-3,14(4H)-dione (25 mg, 58.7 μmol) and (S)-3-hydroxybutyric acid (11.03 mg, 105.96 μmol) were added to DMF (1 mL) and stirred for 5 minutes. DIPEA (27.39 mg, 211.91 μmol) and HATU (40.28 mg, 105.94 μmol) were added and stirred at 25°C for 1 hour. The reaction solution was directly prepared by HPLC and freeze-dried to obtain the title compound (11.9 mg, 22.55 μmol).

[0512] Its structural characterization data are as follows:

[0513] MS m / z(ESI):512.2[M+H] +

[0514] 1 H NMR(400MHz,DMSO-d6)1H NMR (400MHz, DMSO) δ8.66(t,J=5.6Hz,1H),8.39(s,1H),8.26(s,1H),7.32(s,1H),6.54(br,1H),5.46(s,2H), 5.44(s,2H),4.82(d,J=5.6Hz,2H),3.97-3.91(m,1H),2.59(s,3H),2.26-2.21(m,1H),2.16-2.10(m,1H),1.92 -1.81(m,2H),1.00(d,J=6.0Hz,3H),0.87(t,J=7.2Hz,3H).

[0515] The preparation method is as follows:

[0516] Chromatographic column: Waters SunFire Prep C18OBD (5μm*19mm*150mm)

[0517] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% trifluoroacetic acid)

[0518] Biological evaluation

[0519] 1. Tumor Cell Proliferation Inhibition Test

[0520] 1. Inhibitory effect of the compound on HT29 cell proliferation

[0521] (1) Cell plating: First, culture HT29 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The tumor cell sources are shown in Table 1.

[0522] Table 1. Tumor cell sources

[0523] Co-incubation of the compound of the present invention and tumor cells: Cell suspensions were added to 96-well plates respectively. After the cells adhered to the wall, bioactive molecules (compounds of the present invention) diluted with culture medium were added to the wells of the plates and incubated.

[0524] In vitro cell activity assay: After incubation, add Cell Counting-Lite TM 2.0 reagent, shake and mix in the dark, and after a certain reaction time, the test can be carried out and the reading is read on a microplate reader (manufacturer: BMG). The reading of the culture medium well without cells is the background RLU, and the reading of the culture medium well with cells but without compound is the cell control RLU. Cell inhibition rate = 1-(sample RLU-background RLU) / (cell control RLU-background RLU)×100%. According to the four-parameter model fitting curve, the half-maximal inhibitory concentration (IC) of the compound is calculated. 50 ), the test results are shown in Tables 2-1, 2-2, 2-3, 2-4, 2-5, 2-6 and 2-7.

[0525] (2) Data results

[0526] Table 2-1. Inhibitory activity of compounds on HT29 cell proliferation

[0527] Table 2-2. Inhibitory activity of compounds on HT29 cell proliferation

[0528] Table 2-3. Inhibitory activity of compounds on HT29 cell proliferation

[0529] Table 2-4. Inhibitory activity of compounds on HT29 cell proliferation

[0530] Table 2-5. Inhibitory activity of compounds on HT29 cell proliferation

[0531] Table 2-6. Inhibitory activity of compounds on HT29 cell proliferation

[0532] Table 2-7. Inhibitory activity of compounds on HT29 cell proliferation

[0533] The test results show that the compounds of the present invention in Tables 2-1, 2-2, 2-3, 2-4, 2-5, 2-6 and 2-7 have a strong proliferation inhibitory effect on HT29 colon cancer cells.

[0534] 2. Inhibitory effect of compounds on NCI-N87 cell proliferation

[0535] (1) Cell plating: First, culture NCI-N87 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The tumor cell sources are shown in Table 3.

[0536] Table 3. Tumor cell origin

[0537] Co-incubation of the compound of the present invention and tumor cells: Cell suspensions were added to 96-well plates. After the cells adhered to the wall, bioactive molecules (compounds of the present invention) diluted with culture medium were added to the wells and incubated for 72 hours.

[0538] In vitro cell activity assay: After incubation, add Cell Counting-Lite TM 2.0 reagent, shake and mix in the dark, and after a certain reaction time, the test can be carried out and the reading is read on a microplate reader (manufacturer: BMG). The reading of the culture medium well without cells is the background RLU, and the reading of the culture medium well with cells but without compound is the cell control RLU. Cell inhibition rate = 1-(sample RLU-background RLU) / (cell control RLU-background RLU)×100%. According to the four-parameter model fitting curve, the half-maximal inhibitory concentration (IC) of the compound is calculated. 50 ), and the test results are shown in Tables 4-1, 4-2, 4-3, 4-4, 4-5, 4-6 and 4-7.

[0539] (2) Data results

[0540] Table 4-1. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0541] Table 4-2. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0542] Table 4-3. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0543] Table 4-4. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0544] Table 4-5. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0545] Table 4-6. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0546] Table 4-7. Inhibitory activity of compounds on NCI-N87 cell proliferation

[0547] The test results show that the compounds of the present invention in Tables 4-1, 4-2, 4-3, 4-4, 4-5, 4-6 and 4-7 have significant inhibitory effects on the proliferation of NCI-N87 human gastric cancer cells.

[0548] 3. Inhibitory effect of the compounds on HCC1954 cell proliferation

[0549] (1) Cell plating: First, culture HCC1954 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The tumor cell sources are shown in Table 5.

[0550] Table 5. Tumor cell origin

[0551] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecules (compound of the present invention) are added to the above plate wells and incubated.

[0552] In vitro cell viability assay: After incubation, add Cell Counting-Lite™ 2.0 reagent to each well, oscillate to mix in the dark, and after a certain reaction time, perform the assay and read the results using a microplate reader (manufacturer: BMG). The background RLU is calculated using the readings from the wells containing culture medium without cells, and the vehicle RLU is calculated using the readings from the wells containing culture medium without compounds. Cell inhibition rate = 1-(sample RLU-background RLU) / (vehicle RLU-background RLU) × 100%. The half-maximal inhibitory concentration (IC) of the compound is calculated using the four-parameter curve fitting model. 50 RLU (relative light unit): The test results are shown in Tables 6-1, 6-2, 6-3, 6-4, 6-5, and 6-6.

[0553] (2) Data results

[0554] Table 6-1. Antiproliferation activity of compounds on HCC1954 cells

[0555] Table 6-2. Inhibitory activity of compounds on HCC1954 cell proliferation

[0556] Table 6-3. Inhibitory activity of compounds on HCC1954 cell proliferation

[0557] Table 6-4. Inhibitory activity of compounds on HCC1954 cell proliferation

[0558] Table 6-5. Inhibitory activity of compounds on HCC1954 cell proliferation

[0559] Table 6-6. Inhibitory activity of compounds on HCC1954 cell proliferation

[0560] The test results show that the compounds of the present invention in Tables 6-1, 6-2, 6-3, 6-4 and 6-5 have an inhibitory effect on the proliferation of HCC1954 human breast cancer cells.

[0561] 4. Inhibitory effect of compounds on NCI-H1975 cell proliferation

[0562] (1) Cell plating: First, culture NCI-H1975 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The tumor cell sources are shown in Table 7.

[0563] Table 7. Tumor cell sources

[0564] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecules (compound of the present invention) are added to the above plate wells and incubated.

[0565] In vitro cell viability assay: After incubation, add Cell Counting-Lite™ 2.0 reagent to each well, oscillate to mix in the dark, and after a certain reaction time, perform the assay and read the results using a microplate reader (manufacturer: BMG). The background RLU is calculated using the readings from the wells containing culture medium without cells, and the vehicle RLU is calculated using the readings from the wells containing culture medium without compounds. Cell inhibition rate = 1-(sample RLU-background RLU) / (vehicle RLU-background RLU) × 100%. The half-maximal inhibitory concentration (IC) of the compound is calculated using the four-parameter curve fitting model. 50 RLU (relative light unit): The test results are shown in Tables 8-1, 8-2, 8-3, 8-4, 8-5, 8-6, and 8-7.

[0566] (2) Data results

[0567] Table 8-1. Antiproliferation activity of compounds on NCI-H1975 cells

[0568] Table 8-2. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0569] Table 8-3. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0570] Table 8-4. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0571] Table 8-5. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0572] Table 8-6. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0573] Table 8-7. Inhibitory activity of compounds on NCI-H1975 cell proliferation

[0574] The test results show that the compounds of the present invention in Tables 8-1, 8-2, 8-3, 8-4, 8-5, 8-6 and 8-7 have an inhibitory effect on the proliferation of NCI-H1975 human non-small cell lung cancer cells.

[0575] The structures of the comparative compounds are shown below:

[0576] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details based on all the teachings disclosed, and these changes are all within the scope of protection of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite, and prodrug thereof: in, R1 is fluorine or chlorine, When R1 is fluorine, R2 is methyl or chlorine; When R1 is chlorine, R2 is methyl; Alternatively, R1 and R2 together with the ring-forming carbon atoms to which R1 and R2 are respectively connected form a five-membered oxygen-containing heterocyclic ring. R3 is hydrogen or methyl; A is selected from: When R1 is fluorine and R2 is methyl, A is not hydroxyacetamide.

2. The compound of claim 1 or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope-labeled substances, metabolites and prodrugs, wherein R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 and the ring-forming carbon atoms connecting R1 and R2 respectively are Formation R3 is methyl; A is selected from:

3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite, and prodrug thereof, wherein R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl; R3 is methyl; A is selected from:

4. The compound of claim 1 or 2 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite, and prodrug thereof, wherein R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring-forming carbon atoms to which R1 and R2 are respectively connected form R3 is methyl; A is selected from:

5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite and prodrug thereof, wherein R1 is fluorine, R2 is chlorine, or R1 is chlorine, R2 is methyl; R3 is methyl; A is selected from:

6. The compound of claim 1 or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope-labeled substances, metabolites and prodrugs, wherein R1 is fluorine, R2 is methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring-forming carbon atoms to which R1 and R2 are respectively connected form R3 is hydrogen; A is selected from:

7. The compound of claim 1 or 6 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite, and prodrug thereof, wherein R1 is fluorine, R2 is methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring-forming carbon atoms to which R1 and R2 are respectively connected form R3 is hydrogen; A is selected from:

8. The compound of claim 1, 6 or 7, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein R1 is fluorine, R2 is methyl or chlorine, or R1 is chlorine, R2 is methyl, or R1 and R2 together with the ring-forming carbon atoms to which R1 and R2 are respectively connected form R3 is hydrogen; A is selected from:

9. A compound represented by formula (II) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite, and prodrug thereof: in, R1 is halogen, R2 is substituted or unsubstituted C 1-6 alkyl; Alternatively, R1 and R2, together with the ring-forming carbon atoms to which R1 and R2 are respectively attached, form a substituted or unsubstituted heterocyclic ring; R3 is selected from hydrogen or substituted or unsubstituted C 1-6 alkyl; and A is selected from the following substituted or unsubstituted groups:

10. The compound of claim 9 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: R1 is fluorine; R2 is methyl or chlorine; R3 is hydrogen; 11. The compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite and prodrug thereof, wherein the compound has the structure shown below:

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, and one or more pharmaceutically acceptable carriers.

13. A medicine kit product, comprising: a) at least one compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled, metabolite or prodrug thereof, or a pharmaceutical composition according to claim 12 as a first therapeutic agent; b) optionally at least one additional therapeutic agent as a second therapeutic agent, or a pharmaceutical composition comprising an additional therapeutic agent as a second pharmaceutical composition; and c) optional packaging and / or instructions.

14. Use of the compound according to any one of claims 1 to 11 or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope labels, metabolites and prodrugs, the pharmaceutical composition according to claim 12 or the kit product according to claim 13 in the preparation of a drug for treating a disease associated with abnormal cell proliferation; Preferably, the disease is a tumor, such as an advanced solid tumor; Preferably, the tumor is selected from lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female reproductive tract cancer, carcinoma in situ, lymphoma, neurofibroma, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.

15. A method for treating a disease associated with abnormal cell proliferation, comprising the following steps: administering a therapeutically effective amount of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite and prodrug thereof, or a pharmaceutical composition according to claim 12 or a kit product according to claim 13 to an individual in need thereof; Preferably, the disease is a tumor, such as an advanced solid tumor; Preferably, the tumor is selected from lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female reproductive tract cancer, carcinoma in situ, lymphoma, neurofibroma, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.

16. The compound according to any one of claims 1 to 11 or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope-labeled substances, metabolites and prodrugs, the pharmaceutical composition according to claim 12 or the kit product according to claim 13, for use in treating diseases associated with abnormal cell proliferation; Preferably, the disease is a tumor, such as an advanced solid tumor; Preferably, the tumor is selected from lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female reproductive tract cancer, carcinoma in situ, lymphoma, neurofibroma, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.

Citation Information

Patent Citations

  • Camptothecin derivative, method for preparing same, pharmaceutical composition and use thereof

    CN103814036A

  • Fused ring compound, pharmaceutical composition containing fused ring compound, and preparation method and application of fused ring compound

    CN111285882A

  • Camptothecin peptide conjugates

    CN111936169A

  • Camptothecin derivative, and pharmaceutical composition and use thereof

    WO2023020605A1

  • Camptothecin compound, preparation method therefor and use thereof

    WO2023030364A1